Get the Stockscreener App
47.77
7.92%
3.505
Lb Pharmaceuticals Inc stock is traded at $47.77, with a volume of 295.33K.
It is up +7.92% in the last 24 hours and up +49.20% over the past month.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
See More
Previous Close:
$44.27
Open:
$44.24
24h Volume:
295.33K
Relative Volume:
0.97
Market Cap:
$1.54B
Revenue:
-
Net Income/Loss:
$-38.95M
P/E Ratio:
-32.16
EPS:
-1.4857
Net Cash Flow:
$-50.43M
1W Performance:
-0.47%
1M Performance:
+49.20%
6M Performance:
+104.69%
1Y Performance:
+0.00%
1-Day Range:
$43.64
$47.88
1-Week Range:
$43.61
$48.94
52-Week Range:
$13.36
$49.14
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Name
Lb Pharmaceuticals Inc
Sector
Industry
Phone
917-450-6581
Address
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
47.77 | 1.46B | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | H.C. Wainwright | Buy |
| Apr-10-26 | Initiated | Craig Hallum | Buy |
| Jan-09-26 | Initiated | Roth Capital | Buy |
| Oct-06-25 | Initiated | Leerink Partners | Outperform |
| Oct-06-25 | Initiated | Piper Sandler | Overweight |
| Oct-06-25 | Initiated | Stifel | Buy |
View All
Lb Pharmaceuticals Inc Stock (LBRX) Latest News
LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen - MarketBeat
LB Pharmaceuticals (LBRX) investor group reports 5.0% beneficial stake in 13G/A - Stock Titan
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook By Investing.com - Investing.com South Africa
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook - Investing.com
LB Pharmaceuticals Inc Common Stock (NASDAQ: LBRX) Stock Price, News & Analysis - Kalkine
BMO Capital Markets Increases LB Pharmaceuticals (NASDAQ:LBRX) Price Target to $54.00 - MarketBeat
LBRX SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Form 8K LB Pharmaceuticals Inc For: 11 August - Investing.com India
LB Pharmaceuticals Inc Stock 12‑Month Price Target Raised to $47.67, Implies 4% Upside - TradingView
LB Pharmaceuticals Submits Q2 2026 SEC Form 10-Q Reporting 32.26M Shares Outstanding - Kalkine Media
LB Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Form 8K LB Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Q2 Loss Per Share Narrows - Yahoo Finance
LB PHARMACEUTICALS INC Q2 2026: Revenue $0 Net loss $(51.6M), EPS $(1.71) — 10-Q Summary - TradingView
Earnings Flash (LBRX) LB Pharmaceuticals Posts Q2 Loss $1.71 a Share, vs. FactSet Est of $0.81 Loss - marketscreener.com
LB Pharmaceuticals reports Q2 2026 net loss of $51.6M, cash $327.8M; pivots LB-102 development - TradingView
LB Pharmaceuticals Q2 net loss widens on higher R&D costs - TradingView
LB Pharmaceuticals Inc.: Q2 Earnings Snapshot - The Daily Gazette
Press Release: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week HighTime to Buy? - MarketBeat
Janus Henderson Group PLC Takes Position in LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
HC Wainwright Issues Optimistic Estimate for LBRX Earnings - MarketBeat
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), LB Pharmaceuticals, Inc. (LBRX) and SpaceX (SPCX) - The Globe and Mail
Price to sales forward of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
Form 4 LB Pharmaceuticals Inc For: 3 August By Investing.com - Investing.com Canada
Piper Sandler reiterates Overweight on LB Pharmaceuticals stock - Investing.com
Piper Sandler reiterates Overweight on LB Pharmaceuticals stock By Investing.com - Investing.com Nigeria
LB Pharmaceuticals (NASDAQ:LBRX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Enterprise value to revenue forward of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
LB Pharmaceuticals Inc Revenue Breakdown – NASDAQ:LBRX - TradingView
Stempoint Capital LP Takes $1.23 Million Position in LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals raises $150M in private placement By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Prices ~$150 Million Private Placement of Stock and Pre-Funded Warrants - TradingView
LB Pharmaceuticals Announces $150 Million Private Placement - GlobeNewswire
LB Pharmaceuticals Secures $150 Million via Private Placement to Advance LB-102 Pipeline Expansion - Kalkine Media
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 1-Year HighWhat's Next? - MarketBeat
Eversept Partners LP Makes New $2.47 Million Investment in LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals Inc (LBRX) Balance Sheet - TradingKey
LB Pharmaceuticals Inc (LBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
LBRX|LB Pharmaceuticals Inc|Price:35.010|Chg%:+0.390 - TradingKey
LB Pharmaceuticals Inc (LBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LB Pharmaceuticals Inc (LBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LB Pharmaceuticals Inc (LBRX) Institutional Confidence - TradingKey
LB Pharmaceuticals Inc (LBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
H.C. Wainwright Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
LB Pharmaceuticals Inc $LBRX is Spruce Street Capital LP's 3rd Largest Position - MarketBeat
Enterprise value to revenue forward of LB Pharmaceuticals Inc – BOATS:LBRX - TradingView
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock - Investing.com
LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained - TipRanks
Lb Pharmaceuticals Inc Stock (LBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):